Guangwei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guangwei Li has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
Jinping Wang
Daqing Oilfield General Hospital 3 , Da Qing, China
26 shared publicationsSiyao He
Department of Endocrinology Fuwai Hospital and Chinese Academy of Medical Sciences Beijing China
23 shared publicationsYali An
Endocrinology Center, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College 1 , Beijing, China
23 shared publicationsQiuhong Gong
Department of Endocrinology Fuwai Hospital and Chinese Academy of Medical Sciences Beijing China
22 shared publicationsYanyan Chen
Center of Endocrinology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
18 shared publicationsHui Li
Department of Cardiology, Daqing Oilfield General Hospital, Daqing, China
16 shared publications
Latest Publications
- 26 August 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 10555-10564
Impact of Metformin Plus Lifestyle Intervention Compared With Lifestyle Intervention Alone on Prediabetes Remission in Participants With Impaired Glucose Regulation: The China DPP Study
Aims: Prediabetes affects 35% of Chinese adults and is associated with increased risks of cardiovascular disease and mortality. However, findings are inconsistent on the effects of lifestyle and pharmacological interventions in the prediabetes population achieving remission. This analysis aimed to compare the effects of metformin plus lifestyle intervention versus lifestyle intervention alone for prediabetes remission. Materials and Methods: This was a secondary analysis of the China Diabetes Prevention Program ( CDPP ), a multicentre unblinded randomised controlled trial of 1678 participants aged 18–70 years with impaired glucose regulation from 43 hospitals across China ( NCT 03441750). Participants were randomly assigned (1:1) using block randomisation stratified by glucose status (impaired fasting glucose or impaired glucose tolerance), presence of hypertension and use of anti‐hypertensive medication. They received either metformin plus lifestyle intervention or lifestyle intervention alone for 2 years. The primary outcome was prediabetes remission rate. Results: During a median follow‐up of 2.03 years, remission was achieved in 262/831 (31.5%) (138/396 men; 124/435 women) participants in the metformin plus lifestyle group versus 213/847 (25.1%) (106/397 men; 107/450 women) in the lifestyle alone group, with similar effects across subgroups. After adjusting for baseline characteristics, addition of metformin increased the rate of remission ( HR 1.39, 95% CI 1.16–1.67, p < 0.001). Higher baseline HbA1c was associated with lower remission rates ( HR 0.23, 95% CI 0.18–0.29, p < 0.001). Conclusions: Adding metformin to a lifestyle intervention significantly improved prediabetes remission rates over lifestyle intervention alone in Chinese adults with impaired glucose regulation. This may be an effective approach for prediabetes management.
- 26 August 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 10555-10564
Impact of Metformin Plus Lifestyle Intervention Compared With Lifestyle Intervention Alone on Prediabetes Remission in Participants With Impaired Glucose Regulation: The China DPP Study
Aims: Prediabetes affects 35% of Chinese adults and is associated with increased risks of cardiovascular disease and mortality. However, findings are inconsistent on the effects of lifestyle and pharmacological interventions in the prediabetes population achieving remission. This analysis aimed to compare the effects of metformin plus lifestyle intervention versus lifestyle intervention alone for prediabetes remission. Materials and Methods: This was a secondary analysis of the China Diabetes Prevention Program ( CDPP ), a multicentre unblinded randomised controlled trial of 1678 participants aged 18–70 years with impaired glucose regulation from 43 hospitals across China ( NCT 03441750). Participants were randomly assigned (1:1) using block randomisation stratified by glucose status (impaired fasting glucose or impaired glucose tolerance), presence of hypertension and use of anti‐hypertensive medication. They received either metformin plus lifestyle intervention or lifestyle intervention alone for 2 years. The primary outcome was prediabetes remission rate. Results: During a median follow‐up of 2.03 years, remission was achieved in 262/831 (31.5%) (138/396 men; 124/435 women) participants in the metformin plus lifestyle group versus 213/847 (25.1%) (106/397 men; 107/450 women) in the lifestyle alone group, with similar effects across subgroups. After adjusting for baseline characteristics, addition of metformin increased the rate of remission ( HR 1.39, 95% CI 1.16–1.67, p < 0.001). Higher baseline HbA1c was associated with lower remission rates ( HR 0.23, 95% CI 0.18–0.29, p < 0.001). Conclusions: Adding metformin to a lifestyle intervention significantly improved prediabetes remission rates over lifestyle intervention alone in Chinese adults with impaired glucose regulation. This may be an effective approach for prediabetes management.
- 10 August 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (10) , 1812-1820
Early Weight Loss in Impaired Glucose Tolerance Is Associated With Reduced Long-term Mortality and Cardiovascular Risk: The Da Qing Diabetes Prevention Outcome Study
OBJECTIVE: To determine whether weight loss during the initial years following diagnosis of impaired glucose tolerance (IGT) is independently associated with reduced long-term mortality and cardiovascular risk. RESEARCH DESIGN AND METHODS: In the Da Qing Diabetes Prevention Study, 540 adults with IGT were categorized into three groups based on their weight change from baseline to the end of a 6-year lifestyle intervention trial: non–weight loss (n = 200), low weight loss (<5%, n = 163), and high weight loss (≥5%, n = 177). Participants were followed for 34 years to assess all-cause mortality, cardiovascular disease (CVD) mortality, and CVD events. Cox models were used to assess associations. RESULTS: Weight loss during the initial 6 years following IGT diagnosis was associated with reduced long-term risks of CVD events and mortality (P = 0.007–0.015). Compared with participants without weight loss, those with weight loss ≥5% had significantly lower risks of CVD death (hazard ratio [HR] 0.56, 95% CI 0.35–0.89), CVD events (HR 0.71, 95% CI 0.52–0.99), hospitalized heart failure (HR 0.48, 95% CI 0.26–0.88), and all-cause death (HR 0.67, 95% CI 0.48–0.95) after adjusting for age, sex, baseline weight, and other covariates. Furthermore, the high weight loss group showed delays in the median time to all-cause mortality and CVD mortality of 2.1 years and 6.5 years, respectively. CONCLUSIONS: Weight loss achieved in the early years after diagnosis of IGT in Chinese adults is associated with substantially lower long-term risks of CVD events and mortality, suggesting the critical importance of early weight management in individuals with prediabetes for improving long-term survival and cardiovascular health.
- 10 August 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (10) , 1812-1820
Early Weight Loss in Impaired Glucose Tolerance Is Associated With Reduced Long-term Mortality and Cardiovascular Risk: The Da Qing Diabetes Prevention Outcome Study
OBJECTIVE: To determine whether weight loss during the initial years following diagnosis of impaired glucose tolerance (IGT) is independently associated with reduced long-term mortality and cardiovascular risk. RESEARCH DESIGN AND METHODS: In the Da Qing Diabetes Prevention Study, 540 adults with IGT were categorized into three groups based on their weight change from baseline to the end of a 6-year lifestyle intervention trial: non–weight loss (n = 200), low weight loss (<5%, n = 163), and high weight loss (≥5%, n = 177). Participants were followed for 34 years to assess all-cause mortality, cardiovascular disease (CVD) mortality, and CVD events. Cox models were used to assess associations. RESULTS: Weight loss during the initial 6 years following IGT diagnosis was associated with reduced long-term risks of CVD events and mortality (P = 0.007–0.015). Compared with participants without weight loss, those with weight loss ≥5% had significantly lower risks of CVD death (hazard ratio [HR] 0.56, 95% CI 0.35–0.89), CVD events (HR 0.71, 95% CI 0.52–0.99), hospitalized heart failure (HR 0.48, 95% CI 0.26–0.88), and all-cause death (HR 0.67, 95% CI 0.48–0.95) after adjusting for age, sex, baseline weight, and other covariates. Furthermore, the high weight loss group showed delays in the median time to all-cause mortality and CVD mortality of 2.1 years and 6.5 years, respectively. CONCLUSIONS: Weight loss achieved in the early years after diagnosis of IGT in Chinese adults is associated with substantially lower long-term risks of CVD events and mortality, suggesting the critical importance of early weight management in individuals with prediabetes for improving long-term survival and cardiovascular health.
- Open Access
- 6 February 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (3)
Association between younger-onset type 2 diabetes and long-term risk of CVD events: a 34-year follow-up of the Da Qing Diabetes Prevention Study
Background and aims: This study aimed to explore whether a younger age of diabetes onset is associated with an increased risk of CVD events. Methods: This study included 621 patients with younger-onset T2DM (age, ≤50 years) and 573 with older-onset T2DM (age, >50 years) from the original Da Qing Diabetes Prevention Study. For comparison, 310 younger individuals without diabetes (age, ≤50 years) were included in the control group. We followed up participants for 34 years to assess the incidence of CVD events. The association between the age of diabetes onset and the risk of CVD events was analysed. Results: The younger-onset T2DM patients had a higher incidence of components of CVD events per 1,000 person-years than those of the older-onset T2DM and younger non-diabetes controls (19.20, 15.14, and 9.22 for stroke, 7.78, 4.67, and 2.15 for myocardial infarction, and 5.38, 2.76, and 1.11 for heart failure, respectively). The more than double high risk of composite CVD events was found in the younger-onset T2DM compared with the older-onset T2DM (HR = 2.05, 95% CI: 1.64–2.55) and non-diabetic controls (HR = 3.45, 95% CI: 2.39–4.98) even after adjusting for the strongest confounder diabetes duration. Conclusions: Chinese adults with younger-onset T2DM have a higher risk of developing CVD events than those with older-onset T2DM over a 34-year follow-up period.
- 6 February 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (3)
Open AccessAssociation between younger-onset type 2 diabetes and long-term risk of CVD events: a 34-year follow-up of the Da Qing Diabetes Prevention Study
Background and aims: This study aimed to explore whether a younger age of diabetes onset is associated with an increased risk of CVD events. Methods: This study included 621 patients with younger-onset T2DM (age, ≤50 years) and 573 with older-onset T2DM (age, >50 years) from the original Da Qing Diabetes Prevention Study. For comparison, 310 younger individuals without diabetes (age, ≤50 years) were included in the control group. We followed up participants for 34 years to assess the incidence of CVD events. The association between the age of diabetes onset and the risk of CVD events was analysed. Results: The younger-onset T2DM patients had a higher incidence of components of CVD events per 1,000 person-years than those of the older-onset T2DM and younger non-diabetes controls (19.20, 15.14, and 9.22 for stroke, 7.78, 4.67, and 2.15 for myocardial infarction, and 5.38, 2.76, and 1.11 for heart failure, respectively). The more than double high risk of composite CVD events was found in the younger-onset T2DM compared with the older-onset T2DM (HR = 2.05, 95% CI: 1.64–2.55) and non-diabetic controls (HR = 3.45, 95% CI: 2.39–4.98) even after adjusting for the strongest confounder diabetes duration. Conclusions: Chinese adults with younger-onset T2DM have a higher risk of developing CVD events than those with older-onset T2DM over a 34-year follow-up period.
- 15 May 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (10) , 1721-1727
Stroke Incidence Evolution in People With Newly Diagnosed Diabetes and Impaired Glucose Tolerance: A 34-Year Follow-up of the Da Qing Diabetes Study
OBJECTIVE: To examine the incidence of stroke in Chinese adults with newly diagnosed type 2 diabetes (NDD), impaired glucose tolerance (IGT), and normal glucose tolerance (NGT) over a 34-year follow-up period. RESEARCH DESIGN AND METHODS: This cohort study included participants with NDD, IGT, and NGT initially identified in 1986 in the Da Qing Diabetes Prevention Study who were followed up for 34 years. Patients with IGT were randomized into a 6-year lifestyle intervention or control group. The stroke incidence and hazard ratios (HRs) were determined across the three glucose-level groups. RESULTS: Over 34 years, the cumulative stroke incidence in the NDD, IGT nonintervention, and IGT intervention groups were 65.4%, 62.8%, and 49.8%, respectively. The annual incidence in the NDD group was significantly higher than that in the NGT group (24.3 vs. 18.5 per 1,000 person-years), after adjusting for age and sex. After adjusting for risk factors, the risk of stroke was significantly higher in the NDD (HR 1.80, 95% CI 1.46–2.21, P < 0.001), IGT nonintervention (HR 1.52, 95% CI 1.11–2.07, P = 0.008), and IGT intervention (HR 1.33, 95% CI 1.17–1.63, P = 0.01) groups than in the NGT group. A reduced stroke risk was observed in the overall IGT intervention group compared with the NDD group (HR 0.77, 95% CI 0.64–0.94, P = 0.009), especially in women (HR 0.64, 95% CI 0.47–0.88, P = 0.006). CONCLUSIONS: Over 34 years, ∼50% of Chinese adults with NDD and IGT experienced stroke. Further efforts in diabetes management and intervention are required.
- 15 May 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (10) , 1721-1727
Stroke Incidence Evolution in People With Newly Diagnosed Diabetes and Impaired Glucose Tolerance: A 34-Year Follow-up of the Da Qing Diabetes Study
OBJECTIVE: To examine the incidence of stroke in Chinese adults with newly diagnosed type 2 diabetes (NDD), impaired glucose tolerance (IGT), and normal glucose tolerance (NGT) over a 34-year follow-up period. RESEARCH DESIGN AND METHODS: This cohort study included participants with NDD, IGT, and NGT initially identified in 1986 in the Da Qing Diabetes Prevention Study who were followed up for 34 years. Patients with IGT were randomized into a 6-year lifestyle intervention or control group. The stroke incidence and hazard ratios (HRs) were determined across the three glucose-level groups. RESULTS: Over 34 years, the cumulative stroke incidence in the NDD, IGT nonintervention, and IGT intervention groups were 65.4%, 62.8%, and 49.8%, respectively. The annual incidence in the NDD group was significantly higher than that in the NGT group (24.3 vs. 18.5 per 1,000 person-years), after adjusting for age and sex. After adjusting for risk factors, the risk of stroke was significantly higher in the NDD (HR 1.80, 95% CI 1.46–2.21, P < 0.001), IGT nonintervention (HR 1.52, 95% CI 1.11–2.07, P = 0.008), and IGT intervention (HR 1.33, 95% CI 1.17–1.63, P = 0.01) groups than in the NGT group. A reduced stroke risk was observed in the overall IGT intervention group compared with the NDD group (HR 0.77, 95% CI 0.64–0.94, P = 0.009), especially in women (HR 0.64, 95% CI 0.47–0.88, P = 0.006). CONCLUSIONS: Over 34 years, ∼50% of Chinese adults with NDD and IGT experienced stroke. Further efforts in diabetes management and intervention are required.
- Open Access
- 22 April 2025
- Published by Springer Nature in BJC Reports
- Vol. 3 (1) , 1-8
Younger-onset type 2 diabetes associated with increased long-term cancer risk in Chinese adults: A 30-year follow-up of the Da Qing Diabetes Study
Background We investigated the association between younger-onset type 2 diabetes, duration of diabetes, and cancer risk based on data from the Da Qing Diabetes Prevention Outcome Study (DQDPOS). Methods The analysis recruited 620 younger-onset (age≤50 years) and 649 older-onset (age>50 years) patients with type 2 diabetes, and 310 younger non-diabetes controls (age≤50 years). Multiple regression analysis was used to test the influence of younger-onset diabetes and duration of diabetes on the long-term risk of cancer. Results The annual incidence of all cancer among the non-diabetes, younger-, and older-onset type 2 diabetes was significantly different (3.7, 5.5, and 4.0/1000 person-years, respectively). The standard Cox analysis revealed that the patients with younger-onset diabetes had a significantly higher risk of cancer than those with older-onset diabetes (hazard ratio [HR]:1.81; 95% confidence interval [CI]:1.20–2.73) and younger non-diabetic controls (HR:2.43; 95% CI:1.34–4.41) after adjustment for diabetes duration and other confounders. Stepwise general linear regression model analysis revealed that a longer diabetes-free time was associated with longer lifetime cancer-free years (partial R2 = 0.36, p < 0.001), in addition to the non-modifiable predictor duration of diabetes. Conclusions Younger-onset type 2 diabetes was significantly associated with an increased risk of cancer beyond the influence of diabetes duration.
- 22 April 2025
- Published by Springer Nature in BJC Reports
- Vol. 3 (1) , 1-8
Open AccessYounger-onset type 2 diabetes associated with increased long-term cancer risk in Chinese adults: A 30-year follow-up of the Da Qing Diabetes Study
Background We investigated the association between younger-onset type 2 diabetes, duration of diabetes, and cancer risk based on data from the Da Qing Diabetes Prevention Outcome Study (DQDPOS). Methods The analysis recruited 620 younger-onset (age≤50 years) and 649 older-onset (age>50 years) patients with type 2 diabetes, and 310 younger non-diabetes controls (age≤50 years). Multiple regression analysis was used to test the influence of younger-onset diabetes and duration of diabetes on the long-term risk of cancer. Results The annual incidence of all cancer among the non-diabetes, younger-, and older-onset type 2 diabetes was significantly different (3.7, 5.5, and 4.0/1000 person-years, respectively). The standard Cox analysis revealed that the patients with younger-onset diabetes had a significantly higher risk of cancer than those with older-onset diabetes (hazard ratio [HR]:1.81; 95% confidence interval [CI]:1.20–2.73) and younger non-diabetic controls (HR:2.43; 95% CI:1.34–4.41) after adjustment for diabetes duration and other confounders. Stepwise general linear regression model analysis revealed that a longer diabetes-free time was associated with longer lifetime cancer-free years (partial R2 = 0.36, p < 0.001), in addition to the non-modifiable predictor duration of diabetes. Conclusions Younger-onset type 2 diabetes was significantly associated with an increased risk of cancer beyond the influence of diabetes duration.
- Open Access
- 15 November 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-10
Influence of impaired glucose tolerance and type 2 diabetes on the multimorbidity cluster of cardiovascular disease and cancer: a post hoc analysis of the Da Qing Diabetes Prevention Outcome Study
This study explored the influence of type 2 diabetes and impaired glucose tolerance (IGT) on the risk of the multimorbidity cluster of cardiovascular disease (CVD) and cancer. A total of 1629 participants in the Da Qing Diabetes Prevention Outcome Study were recruited in the present analysis, including normal glucose tolerance (NGT, N = 492), IGT (N = 540), and newly diagnosed type 2 diabetes (N = 597) groups. Cox proportional hazards analyses were performed to assess the relationship between NGT, IGT, and newly diagnosed type 2 diabetes and the risk of the multimorbidity cluster of CVD and cancer. The incidence rates for multimorbidity cluster CVD and cancer were 1.25, 3.17, and 3.23 per 1000 person-years in people with NGT, IGT, and the newly diagnosed type 2 diabetes groups, respectively, over 34-year follow-up. Cox analysis revealed that diabetes status (as time-dependent variable) was significantly associated with the subsequent increased risk of multimorbidity cluster of CVD and cancer compared with non-diabetes (hazard ratios [HR] = 2.55, 95% confidence interval [CI] 1.51–4.31) after adjustment of potential confounders. Similar analysis showed that this risk was significantly higher in the IGT and newly diagnosed type 2 diabetes groups compared with NGT, with HR of 3.28 (95% CI 1.83–5.87) and HR of 3.90 (95% CI 2.14–7.09), respectively. Whereas compared diabetes with IGT group, this risk was not significantly different. Similar to newly diagnosed type 2 diabetes, IGT is significantly associated with an increased risk of the multimorbidity cluster of CVD and cancer compared with NGT. This finding highlights the urgent need for an active detection of IGT and effective prevention and management of diabetes.
- 15 November 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-10
Open AccessInfluence of impaired glucose tolerance and type 2 diabetes on the multimorbidity cluster of cardiovascular disease and cancer: a post hoc analysis of the Da Qing Diabetes Prevention Outcome Study
This study explored the influence of type 2 diabetes and impaired glucose tolerance (IGT) on the risk of the multimorbidity cluster of cardiovascular disease (CVD) and cancer. A total of 1629 participants in the Da Qing Diabetes Prevention Outcome Study were recruited in the present analysis, including normal glucose tolerance (NGT, N = 492), IGT (N = 540), and newly diagnosed type 2 diabetes (N = 597) groups. Cox proportional hazards analyses were performed to assess the relationship between NGT, IGT, and newly diagnosed type 2 diabetes and the risk of the multimorbidity cluster of CVD and cancer. The incidence rates for multimorbidity cluster CVD and cancer were 1.25, 3.17, and 3.23 per 1000 person-years in people with NGT, IGT, and the newly diagnosed type 2 diabetes groups, respectively, over 34-year follow-up. Cox analysis revealed that diabetes status (as time-dependent variable) was significantly associated with the subsequent increased risk of multimorbidity cluster of CVD and cancer compared with non-diabetes (hazard ratios [HR] = 2.55, 95% confidence interval [CI] 1.51–4.31) after adjustment of potential confounders. Similar analysis showed that this risk was significantly higher in the IGT and newly diagnosed type 2 diabetes groups compared with NGT, with HR of 3.28 (95% CI 1.83–5.87) and HR of 3.90 (95% CI 2.14–7.09), respectively. Whereas compared diabetes with IGT group, this risk was not significantly different. Similar to newly diagnosed type 2 diabetes, IGT is significantly associated with an increased risk of the multimorbidity cluster of CVD and cancer compared with NGT. This finding highlights the urgent need for an active detection of IGT and effective prevention and management of diabetes.
- Open Access
- 4 October 2024
- Published by Wiley in Journal of Diabetes
- Vol. 16 (10) , e70001
Assessing and predicting type 2 diabetes risk with triglyceride glucose‐body mass index in the Chinese nondiabetic population—Data from long‐term follow‐up of Da Qing IGT and Diabetes Study
Aims: We intended to characterize the superiority of triglyceride glucose‐body mass index (TyG‐BMI) in predicting type 2 diabetes mellitus (T2DM) compared with triglyceride glucose (TyG) and homeostatic model assessment for insulin resistance (HOMA‐IR).Methods: A total of 699 nondiabetic participants in the Da Qing IGT and Diabetes Study were involved in the present analysis and classified according to the median of baseline TyG‐BMI, namely the G1 (low TyG‐BMI) and G2 (high TyG‐BMI) groups. Information on developing diabetes was assessed from 1986 to 2020.Results: During the 34‐year follow‐up, after adjustment for confounders, the G2 group had a higher risk of developing type 2 diabetes than the G1 group (hazard ratio [HR]: 1.92, 95% confidence interval [CI]: 1.51–2.45, p < 0.0001). Restricted cubic spline analyses showed that increased TyG‐BMI was linearly related to higher risks of type 2 diabetes (p for non‐linearity>0.05). Time‐dependent receiver operator characteristics curves suggested that TyG‐BMI exhibited higher predictive ability than TyG (6‐year: area under the curve [AUC]TyG‐BMI vs. AUCTyG, 0.78 vs. 0.70, p = 0.03; 34‐year: AUCTyG‐BMI vs. AUCTyG, 0.79 vs. 0.73, p = 0.04) and HOMA‐IR (6‐year: AUCTyG‐BMI vs. AUCHOMA‐IR, 0.78 vs. 0.70, p = 0.07; 34‐year: AUCTyG‐BMI vs. AUCHOMA‐IR, 0.79 vs. 0.71, p = 0.04) in both short and long terms, and the thresholds of TyG‐BMI to predict type 2 diabetes were relatively stable (195.24–208.41) over the 34‐year follow‐up.Conclusions: In this post hoc study, higher TyG‐BMI was associated with an increased risk of type 2 diabetes and demonstrated better predictability than TyG and HOMA‐IR, favoring the application of TyG‐BMI as a potential tool for evaluating the risk of type 2 diabetes in clinical practice. image
- 4 October 2024
- Published by Wiley in Journal of Diabetes
- Vol. 16 (10) , e70001
Open AccessAssessing and predicting type 2 diabetes risk with triglyceride glucose‐body mass index in the Chinese nondiabetic population—Data from long‐term follow‐up of Da Qing IGT and Diabetes Study
Aims: We intended to characterize the superiority of triglyceride glucose‐body mass index (TyG‐BMI) in predicting type 2 diabetes mellitus (T2DM) compared with triglyceride glucose (TyG) and homeostatic model assessment for insulin resistance (HOMA‐IR).Methods: A total of 699 nondiabetic participants in the Da Qing IGT and Diabetes Study were involved in the present analysis and classified according to the median of baseline TyG‐BMI, namely the G1 (low TyG‐BMI) and G2 (high TyG‐BMI) groups. Information on developing diabetes was assessed from 1986 to 2020.Results: During the 34‐year follow‐up, after adjustment for confounders, the G2 group had a higher risk of developing type 2 diabetes than the G1 group (hazard ratio [HR]: 1.92, 95% confidence interval [CI]: 1.51–2.45, p < 0.0001). Restricted cubic spline analyses showed that increased TyG‐BMI was linearly related to higher risks of type 2 diabetes (p for non‐linearity>0.05). Time‐dependent receiver operator characteristics curves suggested that TyG‐BMI exhibited higher predictive ability than TyG (6‐year: area under the curve [AUC]TyG‐BMI vs. AUCTyG, 0.78 vs. 0.70, p = 0.03; 34‐year: AUCTyG‐BMI vs. AUCTyG, 0.79 vs. 0.73, p = 0.04) and HOMA‐IR (6‐year: AUCTyG‐BMI vs. AUCHOMA‐IR, 0.78 vs. 0.70, p = 0.07; 34‐year: AUCTyG‐BMI vs. AUCHOMA‐IR, 0.79 vs. 0.71, p = 0.04) in both short and long terms, and the thresholds of TyG‐BMI to predict type 2 diabetes were relatively stable (195.24–208.41) over the 34‐year follow‐up.Conclusions: In this post hoc study, higher TyG‐BMI was associated with an increased risk of type 2 diabetes and demonstrated better predictability than TyG and HOMA‐IR, favoring the application of TyG‐BMI as a potential tool for evaluating the risk of type 2 diabetes in clinical practice. image
- Open Access
- 19 August 2024
- Published by Wiley in Journal of Diabetes
- Vol. 16 (8) , e13598
Influence of impaired glucose tolerance alone and combined with metabolic syndrome on long‐term risk of cardiovascular events and mortality
Background: This study aimed to investigate the potential differences in the influence of impaired glucose tolerance (IGT) with and without metabolic syndrome (MetS) on cardiovascular (CV) events and mortality.Methods: Participants having IGT with MetS (IGT_MetS), those having IGT without MetS (IGT_non_MetS), and those having normal glucose tolerance (NGT) without MetS (NGT_non_MetS) (N = 246, N = 294, and N = 471, respectively) were included in this study. Cox proportional hazards regression was used to examine the relationship among these three groups and CV events and mortality.Results: Over the 30‐year follow‐up period, 57 (12.1%) participants having NGT_non_MetS, 55 (18.71%) with IGT_non_MetS, and 74 (30.08%) with IGT_MetS experienced CV mortality. After adjusting for risk factors, the hazard ratios for CV mortality were 2 (95% confidence interval [CI], 1.38–2.91) for the IGT_non_MetS group and 2.96 (95% CI, 2.09–4.19) for the IGT_MetS group, compared with the NGT_non_MetS group. Similar patterns were observed for CV events, with hazard ratios of 1.49 (95% CI, 1.19–1.88) for the IGT_non_MetS group and 1.97 (95% CI, 1.58–2.47) for the IGT_MetS group. Sensitivity analysis revealed that the hazard ratios of the IGT_non_MetS and IGT_MetS groups indicated a higher risk of all‐cause mortality, myocardial infarction events or myocardial infarction mortality, and stroke events or stroke mortality compared with that of the NGT_non_MetS group.Conclusion: IGT_non_MetS increased the risk of CV mortality and events. Furthermore, when it occurred in conjunction with MetS, it further increased the risk of CV mortality and events. This suggested that active intervention is required. image
- 19 August 2024
- Published by Wiley in Journal of Diabetes
- Vol. 16 (8) , e13598
Open AccessInfluence of impaired glucose tolerance alone and combined with metabolic syndrome on long‐term risk of cardiovascular events and mortality
Background: This study aimed to investigate the potential differences in the influence of impaired glucose tolerance (IGT) with and without metabolic syndrome (MetS) on cardiovascular (CV) events and mortality.Methods: Participants having IGT with MetS (IGT_MetS), those having IGT without MetS (IGT_non_MetS), and those having normal glucose tolerance (NGT) without MetS (NGT_non_MetS) (N = 246, N = 294, and N = 471, respectively) were included in this study. Cox proportional hazards regression was used to examine the relationship among these three groups and CV events and mortality.Results: Over the 30‐year follow‐up period, 57 (12.1%) participants having NGT_non_MetS, 55 (18.71%) with IGT_non_MetS, and 74 (30.08%) with IGT_MetS experienced CV mortality. After adjusting for risk factors, the hazard ratios for CV mortality were 2 (95% confidence interval [CI], 1.38–2.91) for the IGT_non_MetS group and 2.96 (95% CI, 2.09–4.19) for the IGT_MetS group, compared with the NGT_non_MetS group. Similar patterns were observed for CV events, with hazard ratios of 1.49 (95% CI, 1.19–1.88) for the IGT_non_MetS group and 1.97 (95% CI, 1.58–2.47) for the IGT_MetS group. Sensitivity analysis revealed that the hazard ratios of the IGT_non_MetS and IGT_MetS groups indicated a higher risk of all‐cause mortality, myocardial infarction events or myocardial infarction mortality, and stroke events or stroke mortality compared with that of the NGT_non_MetS group.Conclusion: IGT_non_MetS increased the risk of CV mortality and events. Furthermore, when it occurred in conjunction with MetS, it further increased the risk of CV mortality and events. This suggested that active intervention is required. image
- Open Access
- 9 July 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (7) , e1004419
Non-diabetes status after diagnosis of impaired glucose tolerance and risk of long-term death and vascular complications: A post hoc analysis of the Da Qing Diabetes Prevention Outcome Study
Background: The association between years of non-diabetes status after diagnosis of impaired glucose tolerance (IGT) and the risk of long-term death and cardiovascular outcomes needed to be clarified. Methods and findings: In this post hoc analysis, we included 540 individuals with IGT who participated in the original Da Qing Diabetes Prevention Study (DQDPS). In the DQDPS, all participants were diagnosed with IGT by a 75 g oral glucose tolerance test and randomized to intervention or control groups with a 6-year lifestyle intervention trial. After the completion of the trial, death, cardiovascular events, and microvascular complications were monitored over a 30-year follow-up. In this post hoc analysis, the Cox analysis assessed the extended risk of these outcomes in individuals who either remained non-diabetes status or progressed to diabetes at the end of 2, 4, and 6 years after diagnosis of IGT. In all participants, the difference in the cumulative incidence rate of the outcomes between the diabetes and non-diabetes group gradually increased over 30 years. Compared with the diabetes group, a significantly lower risk of all-cause death (hazard ratio [HR]: 0.74; 95% confidence interval [CI]: 0.57 to 0.97, p = 0.026), cardiovascular events (HR: 0.63; 95% CI: 0.49 to 0.82, p < 0.001), and microvascular complications (HR: 0.62; 95% CI: 0.45 to 0.86, p = 0.004) first emerged in individuals who remained non-diabetes at the 4 years visit, whereas the significant risk reduction in cardiovascular death was first observed at the end of 6 years (HR: 0.56; 95% CI: 0.39 to 0.81, p = 0.002) after adjustment for age, sex, smoking status, BMI, systolic blood pressure, blood glucose, total cholesterol, intervention, and medications (including insulin plus oral hypoglycaemics, antihypertensives, and lipid-lowering agents). The results in the original intervention group alone were similar to the whole group. The main limitations of our study are the limited number of participants and the sole ethnicity of the Chinese population. Conclusions: In this study, we observed that maintaining several years of non-diabetes status after IGT diagnosis was associated with a significant reduction in long-term risk of death and vascular complications, and for most of these outcomes, maintaining at least 4 years of non-diabetes status may be needed to achieve a significant risk reduction.
- 9 July 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (7) , e1004419
Open AccessNon-diabetes status after diagnosis of impaired glucose tolerance and risk of long-term death and vascular complications: A post hoc analysis of the Da Qing Diabetes Prevention Outcome Study
Background: The association between years of non-diabetes status after diagnosis of impaired glucose tolerance (IGT) and the risk of long-term death and cardiovascular outcomes needed to be clarified. Methods and findings: In this post hoc analysis, we included 540 individuals with IGT who participated in the original Da Qing Diabetes Prevention Study (DQDPS). In the DQDPS, all participants were diagnosed with IGT by a 75 g oral glucose tolerance test and randomized to intervention or control groups with a 6-year lifestyle intervention trial. After the completion of the trial, death, cardiovascular events, and microvascular complications were monitored over a 30-year follow-up. In this post hoc analysis, the Cox analysis assessed the extended risk of these outcomes in individuals who either remained non-diabetes status or progressed to diabetes at the end of 2, 4, and 6 years after diagnosis of IGT. In all participants, the difference in the cumulative incidence rate of the outcomes between the diabetes and non-diabetes group gradually increased over 30 years. Compared with the diabetes group, a significantly lower risk of all-cause death (hazard ratio [HR]: 0.74; 95% confidence interval [CI]: 0.57 to 0.97, p = 0.026), cardiovascular events (HR: 0.63; 95% CI: 0.49 to 0.82, p < 0.001), and microvascular complications (HR: 0.62; 95% CI: 0.45 to 0.86, p = 0.004) first emerged in individuals who remained non-diabetes at the 4 years visit, whereas the significant risk reduction in cardiovascular death was first observed at the end of 6 years (HR: 0.56; 95% CI: 0.39 to 0.81, p = 0.002) after adjustment for age, sex, smoking status, BMI, systolic blood pressure, blood glucose, total cholesterol, intervention, and medications (including insulin plus oral hypoglycaemics, antihypertensives, and lipid-lowering agents). The results in the original intervention group alone were similar to the whole group. The main limitations of our study are the limited number of participants and the sole ethnicity of the Chinese population. Conclusions: In this study, we observed that maintaining several years of non-diabetes status after IGT diagnosis was associated with a significant reduction in long-term risk of death and vascular complications, and for most of these outcomes, maintaining at least 4 years of non-diabetes status may be needed to achieve a significant risk reduction.